Pediatrix Medical Group 2024 Third Quarter Conference Call/Webcast Scheduled for Friday, November 1, 2024
Pediatrix Medical Group (NYSE: MD) has announced its upcoming investor conference call and webcast, scheduled for Friday, November 1, 2024, at 9:00 a.m. ET. The event will focus on discussing the company's operational results for the quarter ending September 30, 2024.
A comprehensive press release detailing the results will be issued on the morning of November 1, 2024, prior to the opening of the securities markets. Investors and interested parties can access the conference call and webcast through the company's official website at www.pediatrix.com/investors.
This announcement provides an opportunity for stakeholders to gain insights into Pediatrix Medical Group's financial performance and operational achievements for the third quarter of 2024.
Pediatrix Medical Group (NYSE: MD) ha annunciato la sua prossima conferenza telefonica con gli investitori e il webcast, previsto per venerdì 1 novembre 2024, alle 9:00 ET. L'evento si concentrerà sulla discussione dei risultati operativi dell'azienda per il trimestre che si è concluso il 30 settembre 2024.
Un comunicato stampa dettagliato sui risultati sarà emesso la mattina del 1 novembre 2024, prima dell'apertura dei mercati finanziari. Gli investitori e le parti interessate possono accedere alla conferenza telefonica e al webcast tramite il sito ufficiale dell'azienda a www.pediatrix.com/investors.
Questo annuncio offre un'opportunità agli stakeholder di ottenere informazioni sulle performance finanziarie e i successi operativi di Pediatrix Medical Group per il terzo trimestre del 2024.
Pediatrix Medical Group (NYSE: MD) ha anunciado su próxima conferencia telefónica para inversores y webcast, programada para viernes 1 de noviembre de 2024, a las 9:00 a.m. ET. El evento se centrará en discutir los resultados operativos de la compañía para el trimestre que finalizó el 30 de septiembre de 2024.
Un comunicado de prensa completo detallando los resultados se emitirá la mañana del 1 de noviembre de 2024, antes de la apertura de los mercados de valores. Los inversores y partes interesadas pueden acceder a la conferencia telefónica y al webcast a través del sitio oficial de la empresa en www.pediatrix.com/investors.
Este anuncio brinda una oportunidad para que las partes interesadas obtengan información sobre el desempeño financiero y los logros operativos del Pediatrix Medical Group para el tercer trimestre de 2024.
페디아트릭스 메디컬 그룹 (NYSE: MD)는 2024년 11월 1일 금요일, 오전 9:00 ET에 예정된 투자자 전화 회의 및 웹캐스트를 발표했습니다. 이번 행사는 2024년 9월 30일 종료된 분기의 회사 운영 결과를 논의하는 데 중점을 두게 됩니다.
결과를 자세히 설명하는 보도자료는 2024년 11월 1일 아침, 증권 시장이 개장하기 전에 발행될 예정입니다. 투자자 및 이해관계자는 회사의 공식 웹사이트 www.pediatrix.com/investors를 통해 전화 회의 및 웹캐스트에 접속할 수 있습니다.
이번 발표는 이해관계자에게 2024년 3분기 동안 페디아트릭스 메디컬 그룹의 재무 성과 및 운영 성과에 대한 통찰력을 제공할 기회를 제공합니다.
Pediatrix Medical Group (NYSE: MD) a annoncé sa prochaine conférence téléphonique pour les investisseurs et le webcast, prévu pour vendredi 1er novembre 2024 à 9h00 ET. Cet événement se concentrera sur la discussion des résultats opérationnels de l'entreprise pour le trimestre se terminant le 30 septembre 2024.
Un communiqué de presse complet détaillant les résultats sera publié le matin du 1er novembre 2024, avant l'ouverture des marchés financiers. Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique et au webcast via le site officiel de l'entreprise à www.pediatrix.com/investors.
Cette annonce offre une opportunité aux parties prenantes d'obtenir des informations sur la performance financière et les réalisations opérationnelles de Pediatrix Medical Group pour le troisième trimestre de 2024.
Pediatrix Medical Group (NYSE: MD) hat seine bevorstehende Telefonkonferenz und Webcast für Investoren bekannt gegeben, die für Freitag, den 1. November 2024, um 9:00 Uhr ET geplant ist. Die Veranstaltung konzentriert sich auf die Diskussion der Betriebsergebnisse des Unternehmens für das zum 30. September 2024 endende Quartal.
Eine umfassende Pressemitteilung mit Einzelheiten zu den Ergebnissen wird am Morgen des 1. November 2024 vor der Eröffnung der Börsen veröffentlicht. Investoren und interessierte Parteien können über die offizielle Website des Unternehmens auf die Telefonkonferenz und den Webcast zugreifen unter www.pediatrix.com/investors.
Diese Ankündigung bietet den Interessengruppen die Möglichkeit, Einblicke in die finanzielle Performance und die betrieblichen Erfolge der Pediatrix Medical Group für das dritte Quartal 2024 zu erhalten.
- None.
- None.
The investor conference call will be webcast and can be accessed at Pediatrix’s website, www.pediatrix.com/investors.
ABOUT PEDIATRIX MEDICAL GROUP
Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 5,000 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.
Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the Company’s practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the impact of the Company’s termination of its then third-party revenue cycle management provider and transition to a hybrid revenue cycle management model with one or more new third-party service providers, including any transition costs associated therewith; the impact of surprise billing legislation; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential healthcare reform; the Company’s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company’s ability to comply with the terms of its debt financing arrangements; the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the impact of the divestiture of the Company’s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions or organic growth initiatives; the effects of share repurchases; and the effects of the Company’s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241016632357/en/
Charles Lynch
Senior Vice President, Finance and Strategy
954-384-0175, x 5692
charles.lynch@pediatrix.com
Source: Pediatrix Medical Group, Inc.
FAQ
When is Pediatrix Medical Group (MD) hosting its Q3 2024 earnings call?
How can investors access Pediatrix Medical Group's (MD) Q3 2024 earnings webcast?
What period will Pediatrix Medical Group's (MD) Q3 2024 earnings report cover?
When will Pediatrix Medical Group (MD) release its Q3 2024 earnings press release?
